FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to production of version of alpha-1-antitrypsin, and can be used in medicine for prevention or treatment of deficiency of alpha-1-antitrypsin. The version of alpha-1-antitrypsin is obtained by replacement of amino acid in 4, 9 or 12 position of N-terminus of alpha-1-antitrypsin on asparagine for the purpose of adding the glycosylation site.
EFFECT: invention enables to increase the period of half-life of alpha-1-antitrypsin in the body.
8 cl, 10 dwg, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
| O-SUCCINYL HOMOSERINE-PRODUCING MICROORGANISM AND METHOD OF PRODUCING O-SUCCINYL HOMOSERINE USING THEREOF | 2015 |
|
RU2723183C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| NEW VERSIONS OF HYALURONIDASE WITH IMPROVED STABILITY AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2811464C2 |
| SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
| TREATMENT OF HEADACHE WITH EXCESSIVE USE OF DRUGS WITH ANTIBODIES TO CGRP OR CGRP-R | 2020 |
|
RU2826186C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| MESSENGER RNA VACCINES AGAINST WIDE RANGE OF CORONAVIRUS VARIANTS | 2022 |
|
RU2826172C2 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
